证券代码：301111 证券简称：粤万年青 公告编号：2023-029 广东万年青制药股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日在 公司会议室以现场方式召开公司第二届监事会第十次会议，此前公司已于 2023 年 8 月 14 日及 2023 年 8 月 16 日以电子邮件形式向全体监事发出会议通知和补充通 知。会议由公司监事会主席谢周良先生召集并主持，本次会议应出席的监事 3 名， 实际出席的监事 3 名。公司董事会秘书列席了本次会议。 本次监事会会议的召集、召开和表决程序符合《中华人民共和国公司法》《中 华人民共和国证券法》等法律、法规及《公司章程》等相关规定。 二、监事会会议审议情况 经全体与会监事认真审议，形成以下决议： （一）审议通过了《关于公司 2023 年半年度报告及其摘要的议案》 经审核，监事会认为董事会编制的 2023 年半年度报告及其摘要，符合中国证 监会和深圳证券交易所相关法律、法规的规定，报告内容真实、准确，完整地反 映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 广东万年青制药股份有限公司 第二届监事会第十次会议决议公告 本公司及监事会全体成员 ...

民生证券股份有限公司 关于广东万年青制药股份有限公司 2023 年度半年度持续督导跟踪报告 | 保荐机构名称：民生证券股份有限公司 | 被保荐公司简称：粤万年青 | | --- | --- | | 保荐代表人姓名：杜峰 | 联系电话：010-85127755 | | 保荐代表人姓名：陈雨 | 联系电话：010-85127749 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度 | | | 的情况 | | | （1）是否督导公司建立健全规章制度（包 括但不限于防止关联方占用公司资源的制 | 是 | | 度、募集资金管理制度、内控制度、内部审 | | | 计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月查询一次 | | （2）公司募集资金项目进展是否与信息披 | 是 | | 露文件一致 ...

证券代码：301111 证券简称：粤万年青 公告编号：2023-032 广东万年青制药股份有限公司 2023年半年度募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等相关规定，广东万年青制药股份 有限公司（以下简称"公司"）董事会就 2023 年半年度募集资金存放与实际使用 情况作如下专项报告： （二）募集资金使用及结余情况 截至 2023 年 6 月 30 日，公司募集资金使用情况汇总如下： 1 单位：元 | 项 目 | 金额 | | --- | --- | | 募集资金总额 | 419,200,000.00 | | 减：发行费用 | 49,491,913.40 | | 募集资金净额 | 369,708,086.60 | | 减：募集资金累计投入项目金额 | 88,078,745.96 | | 其中：以前年度募集资金投入项目金额 ...

证券代码：301111 证券简称：粤万年青 公告编号：2023-033 广东万年青制药股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 财政部发布的《企业会计准则—基本准则》和各项具体会计准则、企业会计 准则应用指南、企业会计准则解释公告以及其他相关规定。 （三）变更后采用的会计政策 本次会计政策变更后，公司将执行财政部发布的解释第 16 号。其他未变更部 分，仍按照原会计政策相关规定执行。 本次会计政策变更是广东万年青制药股份有限公司（以下简称"公司"）根 据财政部修订并发布的相关准则而进行的相应变更，不会对公司财务状况、经营 成果和现金流量产生重大影响。 一、本次会计政策变更概述 （一）变更日期及原因 1、2022 年 11 月 30 日，财政部发布了《企业会计准则解释第 16 号》（财会 〔2022〕31 号），其中"关于单项交易产生的资产和负债相关的递延所得税不适 用初始确认豁免的会计处理"内容自 2023 年 1 月 1 日起施行。 根据上述规定要求，公司决定自规定之日起执行新会计准则并变更相应的会 计 ...

证券代码：301111 证券简称：粤万年青 公告编号：2023-027 广东万年青制药股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东万年青制药股份有限公司（以下简称"公司"）于 2023 年 7 月 26 日召开 第二届董事会第十三次会议以及 2023 年 8 月 11 日召开 2023 年第二次临时股东 大会，审议通过了《关于变更公司经营范围、修订<公司章程>并办理工商变更登 记的议案》，具体内容详见公司于 2023 年 7 月 27 日及 8 月 11 日披露于巨潮资讯 网（www.cninfo.com.cn）上的相关公告。 近日，公司完成了上述工商变更登记及《公司章程》的备案手续，并取得了 汕头市市场监督管理局换发的《营业执照》，具体情况如下： 名称：广东万年青制药股份有限公司 统一社会信用代码：9144050019272917XC 类型：股份有限公司（上市） 注册资本：人民币壹亿陆仟万元 法定代表人：欧先涛 成立日期：1981 年 03 月 16 日 住所：汕头市金园工业城潮阳路 16 片区 08 号 经 ...

证券代码：301111 证券简称：粤万年青 公告编号：2023-026 广东万年青制药股份有限公司 2023年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、召开时间 （1）现场会议召开时间：2023 年 8 月 11 日下午 15:30 （2）网络投票时间：深圳证券交易所（"深交所"）交易系统投票时间为： 2023 年 8 月 11 日 9:15-9:25，9:30-11:30，13:00-15:00；深交所互联网投票系 统投票时间为：2023 年 8 月 11 日 9:15-15:00。 2、现场会议召开地点：广东省汕头市金园工业城潮阳路 16 片区 08 号公司 二楼会议室 3、会议召集人：董事会 4、会议召开方式：本次股东大会采用现场表决与网络投票相结合的方式。 5、会议主持人：董事长欧先涛先生 6. 本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股东大 会规则》《深圳证券交易所创业板股 ...

根据中国证券监督管理委员会发布的《上市公司股东大会规则》(以下简称 《股东大会规则》)的要求，国浩律师(广州)事务所(以下简称"本所")接受广 东万年青制药股份有限公司(以下简称"万年青")的委托，指派李彩霞、林嘉豪 律师(以下简称"本所律师")出席万年青 2023 年第二次临时股东大会(以下简称 "本次股东大会")，对本次股东大会的召集与召开程序、出席会议人员与召集 人的资格、表决程序与表决结果等重要事项出具法律意见。 本所及本所律师依据《中华人民共和国公司法》(以下简称《公司法》)、《律 师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规则(试 行)》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格履行了 法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法 律意见书所认定的事实真实、准确、完整，所发表的结论性意见合法、准确，不 存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 北 京 上 海 深 圳 杭 州 广 州 昆 明 天 津 成 都 宁 波 福 州 西 安 南 京 南 宁 济 南 重 庆 苏 州 长 沙 太 原 武 汉 贵 阳 乌鲁木齐 郑 州 ...

证券代码：301111 证券简称：粤万年青 广东万年青制药股份有限公司投资者活动记录表 编号：20230512 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 投资者关系活动 类别 □新闻发布会 □路演活动 □现场参观 □电话会议 □其他： | --- | --- | |--------------|------------------------------------------------------| | 参与单位名称 | 线上参与公司2022年度及2023年第一季度业绩说明会的投资 | | 及人员姓名 | 者 | 时间 2023 年 5 月 12 日 15:00-16:30 地点 同花顺路演平台（https://board.10jqka.com.cn/ir） 董事长、总经理：欧先涛先生 公司接待人员 董事、财务总监、董事会秘书：陈秀燕女士 姓名 独立董事：苏旭东先生 保荐代表人：杜峰先生 | --- | |------------------------------------------------------| | 本次年度业绩说明会采用网络远程的方式进行，公司参会人 | | 员与投资者 ...

Financial Performance - The company's operating revenue for 2022 was ¥283,336,348.33, a decrease of 19.00% compared to ¥349,788,913.72 in 2021[18]. - The net profit attributable to shareholders for 2022 was ¥33,417,538.99, down 41.56% from ¥57,181,856.40 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was ¥23,989,911.12, a decline of 56.38% from ¥54,994,558.06 in 2021[18]. - The basic earnings per share for 2022 was ¥0.21, a decrease of 56.25% compared to ¥0.48 in 2021[18]. - The total assets at the end of 2022 amounted to ¥857,063,372.44, reflecting a 3.74% increase from ¥826,198,080.76 at the end of 2021[18]. - The net assets attributable to shareholders increased by 1.04% to ¥758,671,171.00 at the end of 2022 from ¥750,853,632.01 in 2021[18]. - The net cash flow from operating activities was ¥69,879,889.67, a slight decrease of 2.44% from ¥71,626,612.47 in 2021[18]. - The weighted average return on net assets for 2022 was 4.44%, down from 16.23% in the previous year, a decrease of 11.79%[18]. Market and Industry Trends - The pharmaceutical industry, particularly traditional Chinese medicine, is expected to grow due to increasing health awareness and demand for preventive care[27]. - The government has implemented multiple policies to support the development of traditional Chinese medicine, including the "14th Five-Year Plan" which outlines key tasks and development indicators[28]. - The market for traditional Chinese medicine is projected to expand significantly, driven by an aging population and increasing prevalence of chronic diseases[27]. Research and Development - The company is focusing on enhancing its R&D capabilities in traditional Chinese medicine to meet the rising demand for chronic disease management[27]. - The company has completed the research and development of new products, including the Zhiqin Qingre Heji and Guqi Dongqing Glycoside, aimed at improving market competitiveness[60]. - Ongoing research on the classic Chinese medicine formula "Yixin Pill" aims to develop new anti-fatigue indications, which could become a significant growth point for the company[58]. - The company is conducting a dry granulation process study for the "Anti-inflammatory and Bile-Removing Tablet," which is an environmentally friendly method that reduces costs and energy consumption[58]. - The company has established a diverse R&D model, including independent, joint, and commissioned research, to ensure a rich and sustainable product pipeline[35]. Product and Market Strategy - The company has 101 drug approval numbers, including 32 original innovative products and 10 exclusive varieties[33]. - The company has established a three-in-one sales model consisting of professional academic promotion, agent recruitment, and commercial OTC sales, enhancing market coverage[38]. - The company focuses on expanding its market share through strategic partnerships with distributors and retail pharmacies[41]. - The company aims to explore new growth points by extending its industrial chain and enhancing core competitiveness in a transitioning pharmaceutical market[39]. Corporate Governance - The company has established a complete internal management and control system to enhance governance levels, complying with relevant laws and regulations[100]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal requirements[101]. - The company has a supervisory board with 3 members, including 1 employee representative, fulfilling its supervisory role effectively[102]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations, ensuring autonomous business capabilities[105]. Financial Management and Investments - The company reported a total investment income of ¥11,903,648.28, accounting for 34.25% of total profit[64]. - The company has established a new wholly-owned subsidiary, Guangdong Zhen Aijia Health Technology Co., Ltd., which was included in the consolidated financial statements[54]. - The company reported a significant increase in investment, with a total investment of CNY 964,544,581.27, a 460.39% increase compared to the previous year[71]. - The company has committed to maintaining transparency in shareholder information and ensuring no improper benefits are transferred using company shares[161]. Shareholder and Equity Structure - The company has a total share capital of 160,000,000 shares, with 76.22% being restricted shares[188]. - The controlling shareholder, Guangdong Jinou Health Technology Co., Ltd., holds 45.00% of shares, totaling 72,000,000 shares[194]. - The actual controllers, 欧先涛 and 李映华, have not changed during the reporting period, with 欧先涛 serving as the chairman and general manager[198]. - The company has not reported any penalties or rectification measures during the reporting period[168]. Environmental and Social Responsibility - The company has implemented strict environmental protection measures and was not listed as a key pollutant unit by environmental authorities[138]. - The company has established effective waste management practices, including recycling and safe disposal of hazardous waste[138]. - The company has not engaged in poverty alleviation or rural revitalization initiatives during the reporting period[139].

Financial Performance - The company's revenue for Q1 2023 was ¥79,304,090.52, representing a 31.78% increase compared to ¥60,179,981.94 in the same period last year[5] - Net profit attributable to shareholders was ¥14,816,687.61, up 13.13% from ¥13,096,502.82 year-on-year[5] - The net profit after deducting non-recurring gains and losses increased by 49.30%, reaching ¥10,825,582.19 compared to ¥7,251,132.34 in the previous year[5] - The company's basic and diluted earnings per share both increased by 12.50%, reaching ¥0.09 compared to ¥0.08 in the same period last year[5] - Net profit for Q1 2023 was ¥14,816,637.93, representing a 13.1% increase from ¥13,096,502.82 in Q1 2022[22] - The total comprehensive income attributable to the parent company was CNY 14,816,687.61, an increase from CNY 13,096,502.82 in the previous period, representing a growth of approximately 13.1%[23] Operating Costs and Expenses - The company experienced a 45.31% increase in operating costs, totaling ¥25,924,479.77, primarily due to rising prices of raw materials for traditional Chinese medicine[8] - Operating costs rose by 45.31% year-on-year, exceeding the revenue growth rate[14] - Total operating costs for Q1 2023 were ¥66,187,704.59, up 26.9% from ¥52,114,398.22 in the same period last year[21] - Research and development expenses for Q1 2023 amounted to ¥2,165,209.75, a decrease of 20.1% compared to ¥2,711,800.92 in Q1 2022[22] Cash Flow and Liquidity - The company reported a significant decrease in net cash flow from operating activities, which was -¥20,027,562.27, a decline of 262.79% from ¥12,302,965.05 in the same period last year[9] - Cash inflow from operating activities totaled CNY 77,481,648.86, down from CNY 81,267,104.24, indicating a decrease of about 4.5%[25] - Cash outflow from operating activities increased to CNY 97,509,211.13 from CNY 68,964,139.19, representing an increase of approximately 41.3%[25] - Net cash flow from investing activities was negative at CNY -6,966,477.17, an improvement from CNY -352,087,471.95 in the previous period[26] - Cash and cash equivalents decreased to ¥67,080,839.20 from ¥81,320,931.29, a decline of 17.4%[18] - The company reported cash inflow from investment activities of CNY 55,895,850.70, down from CNY 65,358,093.66, indicating a decrease of about 3.5%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥838,928,029.06, down 2.12% from ¥857,063,372.44 at the end of the previous year[5] - Total liabilities decreased to ¥65,440,243.43 in Q1 2023 from ¥98,392,224.74 in Q1 2022, a reduction of 33.5%[19] - The company's equity attributable to shareholders rose to ¥773,487,858.61 from ¥758,671,171.00, an increase of 1.9%[19] Shareholder Information - The total number of common stock shareholders at the end of the reporting period was 15,968[11] - The top shareholder, Guangdong Jino Health Technology Co., Ltd., holds 45% of the shares, totaling 72 million shares[11] - The total number of restricted shares at the end of the reporting period was 89,861,520 shares, with no shares released during the period[13] Joint Ventures and Expansion - The company established a joint venture, Shantou Beikang Enze Health Management Co., Ltd., with a registered capital of RMB 10 million, where the company holds a 70% stake[14] - The joint venture aims to expand into the maternal and child health management service industry[14] - The first Baby Bella maternal and child care center in Shantou is currently under renovation and is expected to start trial operations in the second half of the year[15] Other Income and Changes - The company reported a 74.61% decrease in other income, which fell to ¥898,626.82 from ¥3,539,913.60 in the previous year[8] - The company's intangible assets increased by 286.07%, amounting to ¥30,217,137.67, due to the need for land price payments[8] Preliminary Report - The first quarter report was not audited, indicating that the figures are preliminary and subject to change[27]